Immunogenicity and safety of an investigational AS02v -adjuvanted hepatitis B vaccine in patients with renal insufficiency who failed to respond or to maintain antibody levels after prior vaccination: Results of two open, randomized, comparative trials

Abstract An investigational AS02v -adjuvanted hepatitis B (HB-AS02) was compared with a licensed conventional recombinant hepatitis B vaccine ( HBVAXPRO ™; Sanofi Pasteur MSD, Lyon, France) in pre-dialysis, peritoneal dialysis and hemodialysis patients aged ≥18 years who had failed either to respond...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2011-02, Vol.29 (6), p.1159-1166
Hauptverfasser:	Tielemans, Christian L, Vlasak, Jiri, Kosa, Dezider, Billiouw, Jean-Marie, Verpooten, Gert A, Mezei, Ilona, Ryba, Miroslav, Peeters, Patrick C, Mat, Olivier, Jadoul, Michel Y, Polakovic, Vladimir, Dhaene, Michel, Treille, Serge, Kuriyakose, Sherine O, Leyssen, Maarten, Houard, Sophie A, Surquin, Murielle
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvant Allergy and Immunology Applied microbiology Biological and medical sciences Cardiovascular disease Confidence intervals Coronary vessels Dialysis Disease prevention Fractures Fundamental and applied biological sciences. Psychology HB-AS02 Heart failure hemodialysis Hepatitis Hepatitis B Human viral diseases immune response Immunogenicity Infections Infectious diseases Licenses Medical sciences Microbiology patients Peritoneal dialysis renal failure Studies Thrombosis Vaccination Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Viral diseases Viral hepatitis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!